Share

May 2017; 4 (3) Clinical/Scientific NotesOpen Access

ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports

Peter Körtvélyessy, Markus Breu, Marc Pawlitzki, Imke Metz, Hans-Jochen Heinze, Mike Matzke, Christian Mawrin, Paulus Rommer, Gabor G. Kovacs, Christian Mitter, Markus Reindl, Wolfgang Brück, Klaus-Peter Wandinger, Hans Lassmann, Romana Höftberger, Frank Leypoldt
First published March 14, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000335
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
3081

Share

Article Information

vol. 4 no. 3 e335
DOI: 
https://doi.org/10.1212/NXI.0000000000000335
PubMed: 
28331892
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 13, 2016
  • Accepted in final form January 3, 2017
  • First Published March 14, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Peter Körtvélyessy, MD*,
    2. Markus Breu, MD*,
    3. Marc Pawlitzki, MD,
    4. Imke Metz, MD,
    5. Hans-Jochen Heinze, MD,
    6. Mike Matzke, MD,
    7. Christian Mawrin, MD,
    8. Paulus Rommer, MD,
    9. Gabor G. Kovacs, MD, PhD,
    10. Christian Mitter, MD,
    11. Markus Reindl, PhD,
    12. Wolfgang Brück, MD, PhD,
    13. Klaus-Peter Wandinger, MD,
    14. Hans Lassmann, MD, PhD,
    15. Romana Höftberger, MD‡ and
    16. Frank Leypoldt, MD, PhD‡
  1. Peter Körtvélyessy, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Eisai gGmbH Commercial entity travel costs

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Eisai GmbH

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Markus Breu, MD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Marc Pawlitzki, MD,
    4. Scientific Advisory Boards:

    1. Novartis advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Novartis, funding for travel to conference 2014-2016

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Imke Metz, MD,
    5. Scientific Advisory Boards:

    1. 1) commercial: advisory board for Roche.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1)commercial: speaker honoraria, travel grants from BiogenIdec, Bayer Healthcare, TEVA, Serono, Novartis, Genzyme.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. research grant from BiogenIdec.

    Research Support, Government Entities:

    1. grants from German Ministry for Education and Research (BMBF, ??German Competence Network Multiple Sclerosis?? (KKNMS), Pattern MS/NMO);

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Hans-Jochen Heinze, MD,
    6. Scientific Advisory Boards:

    1. (1)UKE Hamburg Eppendorf (1)Hertie Institute for Clinical Brain Research (2)Neuro-Nielsen

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Frontiers in Human Neuroscience

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Vice-speaker German Centre for Neurodegenerative Diseases Vice-speaker center grant “SFB 779”

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (2)Deutsche Forschungs Gemeinschaft, DFG (2)BMBF, Bundesministerium f?r Bildung und Forschung (2)SFB 779 (2)Excellence initiative of the state Saxony-Anhalt

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Mike Matzke, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer-Schering, funding for travel and speaker honoraria (2) Merck Serono, funding for travel and speaker honoraria (3) Novartis, funding for travel and speaker honoraria (4) Sanofi-Aventis, funding for travel and speaker honoraria (5) Biogen, funding for travel and speaker honoraria (6) TEVA, funding for travel and speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Merck Serono

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Christian Mawrin, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Paulus Rommer, MD,
    9. Scientific Advisory Boards:

    1. 19 Roche, Merck

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Teva

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Merck, Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Gabor G. Kovacs, MD, PhD,
    10. Scientific Advisory Boards:

    1. Gedeon Richter Plc. pharmaceutical company

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Acta Neuropathologica, Editorial Board member; Neuropathology & Applied Neurobiology, Editorial Board member; Clinical Neuropathology, Executive Advisory Board.

    Patents:

    1. Anti-alpha-synuclein antibody 5G4; shared Patent with AJ Roboscreen, Germany.

    Publishing Royalties:

    1. Neuropathology of Neurodegenerative Diseases: A Practical Guide Cambridge University Press 2014.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Federal Ministry of Health, Austria: Austrian Reference Centre for Human Prion Diseases

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. FP7 EU Project Develage, grant n? 278486.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Christian Mitter, MD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Markus Reindl, PhD,
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. PLOS ONE, academic editor, 2012,

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. The University Hospital and Medical University of Innsbruck (Austria, Markus Reindl) receive payments for antibody assays (NMDAR, AQP4 and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Luebeck, Germany).

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) This study was supported by a research grant from the Austrian Federal Ministery of Science and Economy (grant BIG WIG MS).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Wolfgang Brück, MD, PhD,
    13. Scientific Advisory Boards:

    1. I serve on the advisory board of Genzyme, Novartis, Biogen and Teva Pharma.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I received honoraria for oral presentations from Teva, Sanofi, Genzyme, Novartis, Merck-Serono, Biogen, Roche and Bayer in the last 2 years.

    Editorial Boards:

    1. I am editorial board member of Acta neuropathologica, Therapeutic Advances in Neurological disorders, Multiple Sclerosis International and Neuropathology and Applied Neurobiology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Teva Pharma, (2) Novartis, (3) Biogen, (4) Genzyme

    Research Support, Government Entities:

    1. (1) German Research foundation (DFG SFB TR43): The brain as a target of inflammatory processes, 2008-2015 German ministry for science and education: Competence network multiple sclerosis, 2010-2018 (2) German Ministry for Education and Reserach: Competence Network Multiple Sclerosis, 2009-2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Tschira Foundation German Multiple SClerosis Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Teva Pharma, expert witness, 2015-2016

  13. Klaus-Peter Wandinger, MD,
    14. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Hans Lassmann, MD, PhD,
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I have received speaker and travel honoraria for several scientific meetings from Biogen Idec, Novartis, Roche and Teva.

    Editorial Boards:

    1. I am member of the Editorial Board of several Journals in the fields of Neurology and Neuroscience.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have served as a consultant for Biogen Idec and AMGEN.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Austrian Science Fund, Projects P27744, I 2114;principal investigator; 2014-2017 European Union PITN.GA-316722; Subproject; This funding is not directly related to the respective article

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Romana Höftberger, MD‡ and
    16. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Frank Leypoldt, MD, PhD‡
    17. Scientific Advisory Boards:

    1. (1) Roche

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. Institute of Laboratory Medicine, University Hospital Schleswig-Holstein Campus Kiel, Germany, commercial antibody testing service, 20%, 2014-2016

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (P.K., M.P., H.-J.H., M.M.), Institute of Neuropathology (C.M.), University Hospital Magdeburg; German Center for Neurodegenerative Diseases (DZNE) Magdeburg (P.K.), Germany; Institute of Neurology (M.B., G.G.K., R.H.), Department of Pediatric and Adolescent Medicine (M.B.), Department of Neurology (P.R.), Division of Neuroradiology and Musculoskeletal Radiology (C.M.), Department of Biomedical Imaging and Image-guided Therapy, and Department of Neuroimmunology (H.L.), Center for Brain Research, Medical University of Vienna, Austria; Department of Neuropathology (I.M., W.B.), University Medical Center Göttingen; Leibniz Institute for Neurobiology (H.-J.H.), Magdeburg; Department of Neurology (M.M.), MEDIAN NRZ Flechtingen, Germany; Clinical Department of Neurology (M.R.), Innsbruck Medical University, Austria; Neuroimmunology (K.-P.W., F.L.), Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lübeck; Department of Neurology (K.-P.W.), University Hospital Schleswig-Holstein, Lübeck; and Department of Neurology (F.L.), University Hospital Schleswig-Holstein, Kiel, Germany.
  1. Correspondence to Dr. Körtvélyessy: peter.koertvelyessy{at}med.ovgu.de
View Full Text

Article usage

Article usage: March 2017 to August 2022

AbstractFullPdfSource
Mar 2017107757135Highwire
Mar 201704012pmc
Apr 20172005438Highwire
Apr 201745103109pmc
May 20172237573Highwire
May 2017387685pmc
Jun 201768459142Highwire
Jun 2017295763pmc
Jul 2017444126Highwire
Jul 2017265767pmc
Aug 2017422416Highwire
Aug 2017255154pmc
Sep 2017461924Highwire
Sep 2017247576pmc
Oct 2017311233Highwire
Oct 2017248594pmc
Nov 2017361223Highwire
Nov 2017147181pmc
Dec 2017172619Highwire
Jan 2018243837Highwire
Feb 2018194525Highwire
Mar 2018263532Highwire
Apr 2018274430Highwire
Apr 20182698101pmc
May 2018235353Highwire
Jun 2018246224Highwire
Jun 2018187482pmc
Jul 2018164110Highwire
Aug 2018204022Highwire
Aug 201896878pmc
Sep 2018163021Highwire
Oct 2018206055Highwire
Nov 2018257748Highwire
Dec 20182410646Highwire
Jan 2019206947Highwire
Feb 2019359338Highwire
Mar 2019315529Highwire
Apr 2019313637Highwire
May 2019243827Highwire
Jun 2019294736Highwire
Jul 2019344932Highwire
Aug 2019504722Highwire
Sep 2019373820Highwire
Oct 2019365031Highwire
Nov 2019415719Highwire
Dec 2019505331Highwire
Jan 2020374821Highwire
Feb 2020283827Highwire
Mar 2020263330Highwire
Apr 202043739Highwire
May 202063527Highwire
Jun 202083627Highwire
Jul 202042917Highwire
Aug 202042328Highwire
Sep 2020165555Highwire
Oct 202055530Highwire
Nov 202072428Highwire
Dec 2020102030Highwire
Jan 202192933Highwire
Feb 202152123Highwire
Mar 2021123725Highwire
Apr 202172531Highwire
May 202183034Highwire
Jun 2021113522Highwire
Jul 202183520Highwire
Aug 2021108725Highwire
Sep 202133318Highwire
Oct 2021610345Highwire
Nov 2021614130Highwire
Dec 2021415820Highwire
Jan 2022417425Highwire
Feb 2022108635Highwire
Mar 2022311418Highwire
Apr 202243919Highwire
May 202285435Highwire
Jun 202225328Highwire
Jul 202255013Highwire
Aug 202266620Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Topics Discussed

Alert Me

Advertisement